NA Interstitial Cystitis Market - Industry Trends and Forecast to 2029

Description

List of Tables

The North America interstitial cystitis market is projected to register a substantial CAGR of 10.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

By Severity (Mild to Moderate and Moderate to Severe), Treatment Type (Medications, Bladder Instillations, Botulinum Toxin A, Nerve Stimulation and Surgery), Route of Administration (Oral, Parenteral, Intravesical, Topical, and Others), Mode of Purchase (Over The Counter and Prescription), Patient Type (Pediatric and Adults), End User (Hospitals, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico), Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the North America interstitial cystitis market are:

Rise in prevalence of interstitial cystitis
Increase in the geriatric population

Market Players:

Some of the major players operating in the North America interstitial cystitis market are:

Alvogen
Hikma Pharmaceuticals
Sandoz AG
Sun Pharmaceutical Industries Ltd.
Accord-UK Ltd
Avet Pharmaceuticals Inc.
Lannett
Viatris Inc.
Pfizer, Inc.
Strides Pharma Science Limited
GlaxoSmithKline plc.
Prestige Consumer Healthcare Inc.
Amneal Pharmaceuticals LLC
Zydus Pharmaceuticals, Inc.
Apotex Inc.
Aurobindo Pharma USA
VistaPharm, Inc.
Johnson& Johnson Services, Inc.
Dr. Reddy's Laboratories, Inc.
Teva Pharmaceuticals, Inc.
Bayer AG
Reckitt Benckiser Group PLC

1 INTRODUCTION 56

1.1 OBJECTIVES OF THE STUDY 56
1.2 MARKET DEFINITION 56
1.3 OVERVIEW OF NORTH AMERICA INTERSTITIAL CYSTITIS MARKET 56
1.4 LIMITATIONS 57
1.5 MARKETS COVERED 58

2 MARKET SEGMENTATION 60

2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 CURRENCY AND PRICING 62
2.5 DBMR TRIPOD DATA VALIDATION MODEL 63
2.6 MULTIVARIATE MODELLING 66
2.7 TYPE LIFELINE CURVE 66
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.9 DBMR MARKET POSITION GRID 68
2.10 MARKET APPLICATION COVERAGE GRID 69
2.11 VENDOR SHARE ANALYSIS 70
2.12 SECONDARY SOURCES 71
2.13 ASSUMPTIONS 71

3 EXECUTIVE SUMMARY 72

4 PREMIUM INSIGHTS 74

4.1 PESTEL ANALYSIS 75
4.2 PORTER'S FIVE FORCES 76
4.3 PIPELINE ANALYSIS FOR INTERSTITIAL CYSTITIS TREATMENT MARKET 77
4.4 EPIDEMIOLOGY 78

5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: REGULATIONS 79

5.1 FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES 79
5.2 EUROPEAN MEDICINES AGENCY (EMA) GUIDELINES 80
5.3 JAPAN REGULATORY GUIDANCE 81

6 MARKET OVERVIEW 82

6.1 DRIVERS 84
- 6.1.1 INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC) 84
- 6.1.2 RISE IN HEALTHCARE EXPENDITURE 84
- 6.1.3 STRATEGIC INITIATIVES OF KEY PLAYERS 85
- 6.1.4 INCREASE IN R&D EFFORTS IN THE HEALTHCARE INDUSTRY 85
- 6.1.5 RISING DISEASE MANAGEMENT PROGRAMS 85
6.2 RESTRAINTS 86
- 6.2.1 HIGH COST OF TREATMENT OF INTERSTITIAL CYSTITIS 86
- 6.2.2 LACK OF AWARENESS ABOUT BLADDER DISORDERS-RELATED PROBLEMS 86
- 6.2.3 DEARTH OF SKILLED PROFESSIONALS 87
6.3 OPPORTUNITIES 87
- 6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 87
- 6.3.2 INCREASE IN DRUG APPROVALS AND LAUNCHES 88
- 6.3.3 IMPROVING HEALTHCARE SYSTEM 88
- 6.3.4 COMBINATION OF DIFFERENT TARGET THERAPIES 88
6.4 CHALLENGES 89
- 6.4.1 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL 89
- 6.4.2 PATENT EXPIRY OF DRUGS 90

7 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY 91

7.1 OVERVIEW 92
7.2 MILD TO MODERATE 95
7.3 MODERATE TO SEVERE 95

8 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE 96

8.1 OVERVIEW 97
8.2 MEDICATIONS 100
- 8.2.1 ANALGESICS 100
  - 8.2.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 101
    - 8.2.1.1.1 IBUPROFEN 101
    - 8.2.1.1.2 NAPROXEN 101
    - 8.2.1.1.3 OTHERS 101
  - 8.2.1.2 ACETAMINOPHEN 101
  - 8.2.1.3 NON-NARCOTIC PAIN MEDICATION 101
    - 8.2.1.3.1 METHENAMINE 102
    - 8.2.1.3.2 PHENAZOPYRIDINE 102
    - 8.2.1.3.3 OTHERS 102
  - 8.2.1.4 NARCOTIC PAIN MEDICATION 102
    - 8.2.1.4.1 CODEINE 103
    - 8.2.1.4.2 HYDROCODONE 103
    - 8.2.1.4.3 OXYCODONE 103
    - 8.2.1.4.4 OXYMORPHONE 103
    - 8.2.1.4.5 MORPHINE 103
    - 8.2.1.4.6 HYDROMORPHONE 103
    - 8.2.1.4.7 METHADONE 104
    - 8.2.1.4.8 OTHERS 104
- 8.2.2 ANTIHISTAMINES 104
  - 8.2.2.1 LORATADINE 104
  - 8.2.2.2 HYDROXYZINE 104
  - 8.2.2.3 OTHERS 104
- 8.2.3 TRICYCLIC ANTIDEPRESSANTS 104
  - 8.2.3.1 AMITRIPTYLINE 105
  - 8.2.3.2 IMIPRAMINE 105
  - 8.2.3.3 OTHERS 105
- 8.2.4 IMMUNOSUPPRESSANTS 105
  - 8.2.4.1 CYCLOSPORINE 105
  - 8.2.4.2 MYCOPHENOLATE 105
  - 8.2.4.3 OTHERS 106
- 8.2.5 PENTOSAN POLYSULFATE SODIUM 106
- 8.2.6 OTHERS 106
  - 8.2.6.1 ALPHA BLOCKERS 106
    - 8.2.6.1.1 DOXAZOSIN 107
    - 8.2.6.1.2 TERAZOSIN 107
    - 8.2.6.1.3 TAMSULOSIN 107
    - 8.2.6.1.4 OTHERS 107
  - 8.2.6.2 AMPHETAMINES 107
  - 8.2.6.3 LEUKOTRIENE INHIBITORS 107
    - 8.2.6.3.1 MONTELUKAST 108
    - 8.2.6.3.2 ZAFIRLUKAST 108
    - 8.2.6.3.3 OTHERS 108
  - 8.2.6.4 OTHERS 108
8.3 BLADDER INSTILLATIONS 108
- 8.3.1 DIMETHYL SULFOXIDE 109
- 8.3.2 HEPARIN 109
- 8.3.3 OTHERS 109
8.4 BOTULINUM TOXIN A 109
8.5 SURGERY 110
- 8.5.1 FULGURATION 110
- 8.5.2 RESECTION 110
- 8.5.3 BLADDER AUGMENTATION 110
8.6 NERVE STIMULATIONS 110

9 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION 112

9.1 OVERVIEW 113
9.2 ORAL 116
- 9.2.1 TABLETS 116
  - 9.2.1.1 EXTENDED RELEASE 117
  - 9.2.1.2 IMMEDIATE RELEASE 117
- 9.2.2 CAPSULES 117
- 9.2.3 OTHERS 117
9.3 PARENTERAL 117
9.4 INTRAVESICAL 118
9.5 TOPICAL 118
9.6 OTHERS 119

10 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE 120

10.1 OVERVIEW 121
10.2 OVER THE COUNTER 124
10.3 PRESCRIPTION 124

11 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE 125

11.1 OVERVIEW 126
11.2 ADULTS 129
11.3 PEDIATRIC 129

12 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY END USER 130

12.1 OVERVIEW 131
12.2 HOSPITALS 134
12.3 CLINICS 134
12.4 HOME HEALTHCARE 135
12.5 OTHERS 135

13 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL 136

13.1 OVERVIEW 137
13.2 DIRECT TENDER 140
13.3 RETAIL SALES 140
- 13.3.1 PHARMACY STORES 141
- 13.3.2 ONLINE RETAIL CHANNEL 141
- 13.3.3 OTHERS 141
13.4 OTHERS 141

14 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY GEOGRAPHY 142

14.1 NORTH AMERICA 143
- 14.1.1 U.S. 154
- 14.1.2 CANADA 160
- 14.1.3 MEXICO 166

15 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY LANDSCAPE 172

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 172

16 SWOT ANALYSIS 173

17 COMPANY PROFILE 174

17.1 TEVA PHARMACEUTICALS INDUSTRIES LTD. 174
- 17.1.1 COMPANY SNAPSHOT 174
- 17.1.2 REVENUE ANALYSIS 174
- 17.1.3 PRODUCT PORTFOLIO 175
- 17.1.4 RECENT DEVELOPMENTS 175
17.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG) 176
- 17.2.1 COMPANY SNAPSHOT 176
- 17.2.2 REVENUE ANALYSIS 176
- 17.2.3 COMPANY SHARE ANALYSIS 177
- 17.2.4 PRODUCT PORTFOLIO 177
- 17.2.5 RECENT DEVELOPMENT 177
17.3 HIKMA PHARMACEUTICALS PLC 178
- 17.3.1 COMPANY SNAPSHOT 178
- 17.3.2 REVENUE ANALYSIS 178
- 17.3.3 COMPANY SHARE ANALYSIS 179
- 17.3.4 PRODUCT PORTFOLIO 179
- 17.3.5 RECENT DEVELOPMENTS 179
17.4 DR. REDDY'S LABORATORIES LTD 180
- 17.4.1 COMPANY SNAPSHOT 180
- 17.4.2 REVENUE ANALYSIS 180
- 17.4.3 COMPANY SHARE ANALYSIS 181
- 17.4.4 PRODUCT PORTFOLIO 181
- 17.4.5 RECENT DEVELOPMENT 182
17.5 BAYER AG 183
- 17.5.1 COMPANY SNAPSHOT 183
- 17.5.2 REVENUE ANALYSIS 183
- 17.5.3 COMPANY SHARE ANALYSIS 184
- 17.5.4 PRODUCT PORTFOLIO 184
- 17.5.5 RECENT DEVELOPMENT 184
17.6 AMNEAL PHARMACEUTICAL LLC. 185
- 17.6.1 COMPANY SNAPSHOT 185
- 17.6.2 REVENUE ANALYSIS 185
- 17.6.3 PRODUCT PORTFOLIO 186
- 17.6.4 RECENT DEVELOPMENTS 186
17.7 APOTEX 187
- 17.7.1 COMPANY SNAPSHOT 187
- 17.7.2 PRODUCT PORTFOLIO 187
- 17.7.3 RECENT DEVELOPMENT 187
17.8 AUROBINDO PHARMA USA 188
- 17.8.1 COMPANY SNAPSHOT 188
- 17.8.2 REVENUE ANALYSIS 188
- 17.8.3 PRODUCT PORTFOLIO 189
- 17.8.4 RECENT DEVELOPMENT 189
17.9 AVET PHARMACEUTICALS INC. 190
- 17.9.1 COMPANY SNAPSHOT 190
- 17.9.2 PRODUCT PORTFOLIO 190
- 17.9.3 RECENT DEVELOPMENT 190
17.10 ALVOGEN 191
- 17.10.1 COMPANY SNAPSHOT 191
- 17.10.2 PRODUCT PORTFOLIO 191
- 17.10.3 10.3RECENT DEVELOPMENT 191
17.11 ACCORD-UK LTD 192
- 17.11.1 COMPANY SNAPSHOT 192
- 17.11.2 PRODUCT PORTFOLIO 192
- 17.11.3 11.3RECENT DEVELOPMENT 192
17.12 GLAXOSMITHKLINE PLC 193
- 17.12.1 COMPANY SNAPSHOT 193
- 17.12.2 12.2REVENUE ANALYSIS 193
- 17.12.3 PRODUCT PORTFOLIO 194
- 17.12.4 RECENT DEVELOPMENT 194
17.13 JOHNSON & JOHNSON SERVICES, INC. 195
- 17.13.1 COMPANY SNAPSHOT 195
- 17.13.2 REVENUE ANALYSIS 195
- 17.13.3 PRODUCT PORTFOLIO 196
- 17.13.4 RECENT DEVELOPMENT 196
17.14 LANNETT 197
- 17.14.1 COMPANY SNAPSHOT 197
- 17.14.2 REVENUE ANALYSIS 197
- 17.14.3 PRODUCT PORTFOLIO 198
- 17.14.4 RECENT DEVELOPMENT 198
17.15 PRESTIGE CONSUMER HEALTHCARE 199
- 17.15.1 COMPANY SNAPSHOT 199
- 17.15.2 REVENUE ANALYSIS 199
- 17.15.3 PRODUCT PORTFOLIO 200
- 17.15.4 RECENT DEVELOPMENTS 200
17.16 PFIZER INC. 201
- 17.16.1 COMPANY SNAPSHOT 201
- 17.16.2 REVENUE ANALYSIS 201
- 17.16.3 PRODUCT PORTFOLIO 202
- 17.16.4 RECENT DEVELOPMENT 202
17.17 RECKITT BENCKISER GROUP PLC. 203
- 17.17.1 COMPANY SNAPSHOT 203
- 17.17.2 REVENUE ANALYSIS 203
- 17.17.3 PRODUCT PORTFOLIO 203
- 17.17.4 RECENT DEVELOPMENT 204
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD. 205
- 17.18.1 COMPANY SNAPSHOT 205
- 17.18.2 REVENUE ANALYSIS 205
- 17.18.3 PRODUCT PORTFOLIO 206
- 17.18.4 RECENT DEVELOPMENT 206
17.19 STRIDES PHARMA SCIENCE LIMITED. 207
- 17.19.1 COMPANY SNAPSHOT 207
- 17.19.2 REVENUE ANALYSIS 207
- 17.19.3 PRODUCT PORTFOLIO 208
- 17.19.4 RECENT DEVELOPMENT 208
17.20 VIATRIS INC. 209
- 17.20.1 COMPANY SNAPSHOT 209
- 17.20.2 REVENUE ANALYSIS 209
- 17.20.3 PRODUCT PORTFOLIO 210
- 17.20.4 RECENT DEVELOPMENT 210
17.21 VISTA PHARM INC. 211
- 17.21.1 COMPANY SNAPSHOT 211
- 17.21.2 PRODUCT PORTFOLIO 211
- 17.21.3 RECENT DEVELOPMENTS 211
17.22 ZYDUS PHARMACEUTICALS INC., 212
- 17.22.1 COMPANY SNAPSHOT 212
- 17.22.2 REVENUE ANALYSIS 212
- 17.22.3 PRODUCT PORTFOLIO 213
- 17.22.4 RECENT DEVELOPMENTS 213

18 QUESTIONNAIRE 214

19 RELATED REPORTS 217

LIST OF FIGURES

FIGURE 1 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SEGMENTATION 23
FIGURE 2 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: DATA TRIANGULATION 26
FIGURE 3 NORTH AMERICA BLADDER DISORDERS MARKET: DROC ANALYSIS 27
FIGURE 4 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 28
FIGURE 5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY RESEARCH ANALYSIS 28
FIGURE 6 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: INTERVIEW DEMOGRAPHICS 30
FIGURE 7 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: DBMR MARKET POSITION GRID 31
FIGURE 8 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: MARKET APPLICATION COVERAGE GRID 32
FIGURE 9 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: VENDOR SHARE ANALYSIS 33
FIGURE 10 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SEGMENTATION 36
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF INTERSTITIAL CYSTITIS IS EXPECTED TO DRIVE THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 37
FIGURE 12 MILD TO MODERATE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET IN 2022 & 2029 37
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET 46
FIGURE 14 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2021 55
FIGURE 15 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2022-2029 (USD MILLION) 56
FIGURE 16 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, CAGR (2022-2029) 56
FIGURE 17 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, LIFELINE CURVE 57
FIGURE 18 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2021 60
FIGURE 19 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION) 61
FIGURE 20 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, CAGR (2022-2029) 61
FIGURE 21 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 62
FIGURE 22 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021 76
FIGURE 23 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 77
FIGURE 24 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 77
FIGURE 25 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 78
FIGURE 26 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2021 84
FIGURE 27 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 85
FIGURE 28 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029) 85
FIGURE 29 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE 86
FIGURE 30 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2021 89
FIGURE 31 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION) 90
FIGURE 32 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, CAGR (2022-2029) 90
FIGURE 33 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, LIFELINE CURVE 91
FIGURE 34 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, 2021 94
FIGURE 35 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, 2022-2029 (USD MILLION) 95
FIGURE 36 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, CAGR (2022-2029) 95
FIGURE 37 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, LIFELINE CURVE 96
FIGURE 38 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2021 100
FIGURE 39 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 101
FIGURE 40 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 101
FIGURE 41 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 102
FIGURE 42 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021) 107
FIGURE 43 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021) 109
FIGURE 44 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029) 109
FIGURE 45 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029) 110
FIGURE 46 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029) 110
FIGURE 47 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%) 135